Project Grant R03HD121962
Award Date 7/15/26
Completion Date 6/30/28
Dollars Obligated $312K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Aurora, CO 80045, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded $149,920 to The Regents of the University of Colorado, doing business as University of Colorado-Denver, on January 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds a Project Grant (F31AI194862) titled "Deciphering Central Nervous System Autoimmunity in Down Syndrome." The research examines mechanisms linking interferon receptor triplication in Down syndrome to central...
- The National Institutes of Health Office of the Director awarded the University of New Mexico Health Sciences Center $419,375 on July 1, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to investigate mechanisms of vascular dysfunction in Down syndrome. The research examines endothelial dysfunction and glycocalyx depletion in a mouse model of Down syndrome (TCMAC21 mice) to understand cardiovascular disease risk in the Down syndrome population. The study investigates how...
- Federal Grant Award Summary The University of Colorado received a $430,375 Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), effective July 17, 2025, with a completion date of June 30, 2027. The grant funds research investigating the association between Trisomy 21 (Down's Syndrome) and placentation defects, addressing the elevated risk of adverse pregnancy outcomes in T21 pregnancies due to...
- The National Institutes of Health Office of the Director awarded University of California Irvine $6.132 million on August 1, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to investigate the neurobiological basis for cognitive dysfunction and dementia in aging adults with Down syndrome. The project uses spatial multi-omics techniques—combining transcriptomics, epigenomics, and proteomics—to analyze over 100 clinically characterized brain samples from individuals with Down...
- The Department of Health and Human Services National Institutes of Health Office of the Director awarded the University of Wisconsin System $568,615 on September 2, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to investigate the molecular mechanisms underlying synaptic deficiency in Down syndrome. The research project, titled "Molecular Mechanisms Underlying Synaptic Deficiency in Down Syndrome" (R01HD120347), will use isogenic trisomy 21 disorder-specific human...
- The National Institute of Child Health and Human Development awarded the University of Connecticut Health Center $457,875 on September 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to develop and deploy an inducible gene dosage correction system in Down syndrome organoid and rodent models carrying human chromosome 21. The research uses an XIST-based transgene system to reversibly silence one copy of chromosome 21 across multiple cell types,...
- The National Institute of General Medical Sciences awarded The Regents of The University of Colorado, doing business as University of Colorado-Denver, $429,000 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate chromatin landscape and DNA repair dynamics at dysfunctional telomeres. The research applies a multiscale approach integrating cell and molecular biology, chromatin biology, and single-molecule imaging to understand how...
- The National Institutes of Health Office of the Director awarded the Trustees of Boston University $763,348 on September 1, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to investigate how the HSA21-triplicated gene HMGN1 exacerbates neuropathological features in Down syndrome and Down syndrome-associated Alzheimer's disease. The research will examine HMGN1's dual mechanisms: its role as a nucleosome binding factor that facilitates chromatin accessibility and regulates genes...
- The Department of Health and Human Services National Institutes of Health Office of the Director awarded $845,935 to the Research Institute At Nationwide Children's Hospital on July 21, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to establish a single-cell and spatial atlas of trisomy 21 hearts using both Down syndrome mouse models and patient-specific induced pluripotent stem cells. The award funds research aimed at elucidating cellular and tissue mechanisms of septal...
- The National Institute of Child Health and Human Development awarded ST Jude Children's Research Hospital Inc. $370,000 on August 17, 2026, under the Child Health and Human Development Extramural Research Projects program (CFDA 93.865) to analyze chromosome 21 nondisjunction errors in Down syndrome using a computational framework called MeiHMM. The research applies MeiHMM—a computational method that infers the type of nondisjunction error using only proband genomic data—to approximately 4,500...